INTRODUCTION

Ψ
Completion of the Human Genome Project was a pivotal first step to revolutionize medicine in the 21st century 1 . The completed human genome was found to contain between 30,000 and 35,000 genes, far less than the 100,000 genes predicted when the project commenced in the mid-1990s 2 . Subsequently it was found that one gene can produce more than one protein, each with a different functional capability. The generation of multiple proteins from a single gene can occur as a result of alternate splicing where a single DNA template can produce several different messenger RNAs, each of which is then used to make different proteins different proteins. On average, however, a gene produces five to ten different proteins 4 . Genomics is the systematic use of information on the expression, regulation and structural association of genes. It is used in genetic analysis, measurement of gene expression and determination of gene function
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. As genomics has proven inadequate to predict the structure and dynamic properties of all proteins, a new field of protein study termed proteomics has developed. This is the large-scale study of protein expression, structure and function. It aims to correlate the structural and functional diversity of proteins with underlying biological processes, including disease processes 6 . Proteomics has created opportunities to identify, investigate and target proteins that are differentially expressed in health and disease. Clinical medicine is poised to benefit enormously with the potential to develop better diagnostic and prognostic tests, to identify new therapeutic targets and ultimately to allow patient-individualized therapy. Finding the protein or proteins (biomarker) associated with a disease or adverse event will lead to a much earlier identification of disease, potentially prior to the onset of symptoms 7 . 
TECHNOLOGIES
CLINICAL APPLICATIONS
The potential applications of proteomics in the laboratory revolve around: identifying components of the proteome; comparing the expression of proteins between normal and diseased organs at certain stages of disease; bioinformational analysis to determine how proteins interact with each other in vivo; identification and characterization of proteins post-translationally; study the structure and function of protein complexes to understand the organization of cells at the molecular level. The goal of clinical proteomics and molecular medicine is to assist in the study of characterization of the cellular components and cellular networks to be used in the understanding of the pathology of disease process, diagnosis and patient management. 
Diagnosis of Severe Acute Respiratory
Syndrome: The pathogenesis of severe acute respiratory syndrome (SARS) is not well understood, and a specific diagnostic method is critical for the management and control of this disease. Proteomic analysis of sera from patients with SARS has identified potential biomarkers. These are truncated forms of α (1)-Antitrypsin, which were consistently found in higher concentrations in the sera of SARS patients compared with healthy controls. These markers may prove useful as diagnostic tools and therapeutic targets. Moreover, studies of the protein structure of the SARS virus may reveal potential vaccine targets
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. 21 . Since the advent of prostate specific antigen (PSA) screening, a significant number of men have had a PSA test performed and this has led to a significant increase in the number of diagnosed cases
PROTEOMIC AND CANCER
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. However, the PSA lacks sensitivity and therefore, evaluating multiple proteins will be essential to establishing signature proteomic patterns that distinguish cancer from non-cancer as well as identify all genetic subtypes of the cancer and their biological activity. In one study, proteomic analysis of prostate cancer patients versus healthy controls was carried out by looking for differences in protein patterns between the two groups. Using blood samples from 167 prostate cancer patients, 77 patients with benign prostate hyperplasia and 82 healthy men, protein patterns developed as a classification system had correctly classified 96 percent of the samples as either prostate cancer or non-cancer (benign prostate hyperplasia/healthy men) 23 . A further proteomic approach is to determine whether the changes in specific phosphoproteins believed to be involved in cellular signalling events and cancer progression in prostate cancer patients have been speculated to serve as a biomarker of early disease 24 
.
Breast Cancer: Breast cancer is the most common malignancy among women in the Western world and constitutes 18% of all cancers in women 25 . Traditional prognostic factors include the axillary lymph node status, the tumor size, the nuclear grade and the histologic grade. Interest in novel prognostic markers is based on the fact that a significant number of patients with early-stage breast cancer harbour microscopic metastasis at the time of diagnosis. It is now well established that adjuvant systemic therapy improves survival in patients with early-stage breast cancer. Recent technical advances in mass spectrometry, such as matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) and its variant surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS), have enabled high-throughput proteome analysis
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. A multitude of molecules involved in breast cancer biology have been studied as potential prognostic markers. In one study a combination of three candidate proteins in the blood were found to be useful in discriminating between 169 patients at various stages of breast cancer compared to women with benign breast disease and healthy controls 28 . In other studies, nipple aspirate fluid was used to identify tumor marker candidates
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. Proteomic analysis of breast nipple aspirate fluid (NAF) holds promise as a non-invasive, low cost method to identify markers of breast cancer. These protein molecules when secreted, they represent the final processed form of the marker protein, which makes proteomic analyses less ambiguous to provide clues to changes in protein translational rates, post-translational modification, sequestration, and degradation that lead to disease. Many of the proteins that have been identified in the NAF proteome could potentially be markers of disease, including ras-related protein; metastasisassociated protein; BCL2, which has been implicated in the suppression of cell death; CD5, which is reported to play a role in the inhibition of apoptosis; retinol-binding protein, which has recently been shown to suppress breast cancer cell survival and has been shown to be down-regulated in a subset of breast cancer; clusterin, which has been associated with cell death and apoptosis; and transferrin, which has been assigned a role in cell proliferation 30 .
Bladder Cancer: Bladder cancer incidence varies widely throughout the world. Belgium and Italy, , have the highest recorded incidence rates in Europe (42.5/100,000 and 41/100,000 population respectively), much more than in the United States with an incidence of 24.1/100,000 and an estimated 61,160 newly diagnosed cases in 2007. However,, cancer registries in Slovenia, Croatia, and Switzerland have reported even lower European bladder cancer incidence (10.1/100,000, 11.7/100,000 and 12.0/100,000 respectively) with the lowest rates found in Asian and South American countries. Bladder cancer affects men four times more often than women. The risk of bladder cancer increases with age with over 70 percent of people diagnosed are older than 65 years 31,32 . Biological characteristics of urothelial carcinomas range from benign, superficial, low-grade, non-life threatening, papillary lesions, that respond well to resection and adjuvant treatment but are prone to recurrence to highly invasive malignant carcinomas with grave outcome. Several laboratories have successfully demonstrated that specific protein patterns can be detected from tumor tissue and these could discriminate adequately between diseased and healthy tissue. In the case of bladder cancer, proteomics analysis has identified several keratin proteins that are expressed in different amounts as the disease progresses from the early transitional epithelium stage to full blown squamous cell carcinoma. The measurement of keratin levels in bladder cancer biopsies can therefore be used to monitor the progression of the disease. Another protein, psoriasin, is found in the urine of bladder cancer patients and can be used as an early diagnostic marker for the disease. The study and utilization of these novel markers support the notion that proteomics, but not DNA arrays, can be used in cancer diagnosis. Urine, in common with most bodily fluids, contains proteins but no RNA 33, 34 .
PROTEOMICS AND THERAPEUTICS
Drug Resistance
Drug resistance represents a major clinical obstacle in the management of many infectious diseases, and, in many cases, the mechanism is unknown. Genetic and protein-sequence data for many microorganisms is now available and provides tools for understanding their resistance to drugs and for identifying novel agents for treating drug-resistant disease, such as azole resistance in Candida albicans which has been linked with differential expression of proteins such as Erg10p, a protein involved in the ergosterol biosynthesis pathway. This has been shown as a potential drug target for the treatment of resistant disease 35 .
Chloroquine resistance: Chloroquine has been one of the most successful drugs used to treat malaria but has been rendered virtually ineffective in many parts of the world by the widespread emergence of chloroquine resistance. Proteomics technologies are playing a major role in identifying potential therapeutic targets in Plasmodium species, as well as hostpathogen interactions and protein-drug interactions. Advances to date include the identification of differences between Plasmodium species, identification of immune targets for vaccination and immune protection, better understanding of the cellular target(s) of chloroquine and the mechanisms of chloroquine resistance 36 .
Development of new Therapeutic Agents
Proteomics as an evolving science is expected to have a major impact on drug development in the near future. It has been shown that some proteins which are differentially expressed by microorganisms, and that differ primarily in thier tertiary structure from related proteins in the host have now become potential therapeutic drug targets. These can be tested against commercially available libraries of chemical agents to identify lead compoundscompounds with in vitro activity that can be used to target these protein markers and to represent potential new therapies. Exploitation of these scientific findings could assist to develop improved therapeutic agents to challenge the complexity of various clinical entities.
FUTURE DEVELOPMENTS
At present, it is fairly premature to utilize many of the newly discovered biomarkers using proteomics analyses as screening or diagnostic tools. However, these exploratory studies point to the promise of proteomics as an investigatory tool to be used to screen or diagnose many disease entities using newly discovered biomarkers. Applied research in medical diagnostics is being developed and continues on several metabolic, inherited, infectious and malignant disease entities with construction of proteomic maps of many serum and body fluids biomarkers. These include amniotic fluid biomarkers which are being studied for the complex determination of fetal pathology biomarkers. Moreover, based on dynamics of specific biomarkers' alterations, special attention has been given to elucidation of the pathogenesis and the etiology of female infertility, and of recurrent miscarriages with the elaboration of clinical algorithms for the management of these conditions Further research is needed to examine specific features of posttranslational modification of peptide hormones that could as markers of some pathological processes such as colorectal and breast cancer, to assist with the determination of pharmacogenetic approaches to target and manage these conditions Moreover, continuous utilization of genomics and proteomics to study and examine biomarkers to screen and diagnose malignant tumors, has lead to and continues to discover and evaluate many of the markers for the socalled "silent tumors" of bone, ovaries, pancreas and others. In particular, the determination of proto-oncogene-encoded proteins such as myc, src, fos, jun, myb, fms, and raf-1. This is being carried out as an aid to screening for the presence of these cancers. Further development underway is the construction of proteomic maps of malignant tumor tissues to be used for diagnostic purposes, and to aid an early diagnosis and treatment optimization. Additionally, several studies utilizing proteomics modalities and techniques is now targeting many common disease processes such as the diagnosis of chronic hepatitis, whereby, scientific research have continued to reveal the protein biomarkers of serum Hepatitis B and Hepatitis C viruses to aid in the diagnosis and the control of therapeutic efficacy 37, 38 . Validation of these new tests in large clinical trials is necessary prior to implementing proteomics techniques and patterns routinely in clinical use as tools for early disease detection. It is anticipated that databases of several proteins from tissues, cells and body fluids in health and disease shall soon be available. These will link multiple parameters such as expression of specific proteins and cellular pathways and proliferation with genetic data and disease states that can be used for accurate and rapid diagnosis 39 .
